Removal of albumin and immunoglobulins from canine cerebrospinal fluid using depletion kits: a feasibility study

Fluids and Barriers of the CNS

Reiner F Haseloff¹  Ingolf E Blasig¹  Jean-Michel Heard³  Jérome Ausseil²  Michael Schümann¹  Eberhard Krause¹  Ramona Günther¹ 

[1] Leibniz-Institut für Molekulare Pharmakologie, Robert-Rössle-Str. 10, 13125 Berlin, Germany;Laboratoire de Biochimie, Centre de Biologie Humaine, Hôpital Sud, CHU Amiens, Avenue René Laënnec, 80054 Amiens and Unité INSERM U1088, Pôle Santé, Université de Picardie Jules Verne, Rue des Louvels, 80000 Amiens, France;Institut Pasteur, 25-28 rue du Dr Roux, 75724, Paris, Cedex 15, France

关键词: Mass spectrometry;    Albumin;    Depletion;    Dog;    Cerebrospinal fluid;   

Others  :  800798
DOI  :  10.1186/2045-8118-11-14

 received in 2014-03-14, accepted in 2014-06-13,  发布年份 2014

【 摘 要 】

Background

Highly abundant proteins in biological fluids such as serum or cerebrospinal fluid (CSF) can hinder the detection of proteins in lower abundance, e.g., potential biomarkers. Commercial products are available for the depletion of albumin and immunoglobulins (Igs), although most of these kits have not been validated for dog samples. The present study therefore examines the use of different types of depletion kits for dog CSF.

Findings

Three kits, with different mechanisms for the depletion of albumin and Igs, were tested with dog CSF specimens. One product significantly decreased the amount of albumin; with all kits, IgG was less efficiently removed than albumin. Mass spectrometry of the fractions eluted from the depletion columns revealed considerable co-depletion of other CSF proteins.

Conclusions

A commercially available depletion kit was identified which depletes albumin and (to a lower extent) immunoglobulins from dog CSF. However, the limited efficacy and the concomitant loss of other proteins from the sample should be taken into account when using this product.

【 授权许可】

   
2014 Günther et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Kroksveen AC, Opsahl JA, Aye TT, Ulvik RJ, Berven FS: Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. J Proteomics 2011, 74:371-388.
• [2]Roche S, Gabelle A, Lehmann S: Clinical proteomics of the cerebrospinal fluid: towards the discovery of new biomarkers. Proteomics Clin Appl 2008, 2:428-436.
• [3]da Silva MAO, Arruda MAZ: An aqueous two-phase system as a strategy for serum albumin depletion. Talanta 2009, 77:985-990.
• [4]Ichibangase T, Moriya K, Koike K, Imai K: Limitation of immunoaffinity column for the removal of abundant proteins from plasma in quantitative plasma proteomics. Biomed Chromatogr 2009, 23:480-487.
• [5]Mahn A, Reyes A, Zamorano M, Cifuentes W, Ismail M: Depletion of highly abundant proteins in blood plasma by hydrophobic interaction chromatography for proteomic analysis. J Chromatogr B 2010, 878:1038-1044.
• [6]Ramstrom M, Zuberovic A, Gronwall C, Hanrieder J, Bergquist J, Hober S: Development of affinity columns for the removal of high-abundance proteins in cerebrospinal fluid. Biotechnol Appl Biochem 2009, 52:159-166.
• [7]Urbas L, Brne P, Gabor B, Barut M, Strlic M, Petric TC, Strancar A: Depletion of high-abundance proteins from human plasma using a combination of an affinity and pseudo-affinity column. J Chromatogr A 2009, 1216:2689-2694.
• [8]Wetterhall M, Zuberovic A, Hanrieder J, Bergquist J: Assessment of the partitioning capacity of high abundant proteins in human cerebrospinal fluid using affinity and immunoaffinity subtraction spin columns. J Chromatogr B 2010, 878:1519-1530.
• [9]Mouton-Barbosa E, Roux-Dalvai F, Bouyssie D, Berger F, Schmidt E, Righetti PG, Guerrier L, Boschetti E, Burlet-Schiltz O, Monsarrat B, de Peredo AG: In-depth exploration of cerebrospinal fluid by combining peptide ligand library treatment and label-free protein quantification. Mol Cell Proteomics 2010, 9:1006-1021.
• [10]Gundry RL, White MY, Nogee J, Tchernyshyov I, Van Eyk JE: Assessment of albumin removal from an immunoaffinity spin column: critical implications for proteomic examination of the albuminome and albumin-depleted samples. Proteomics 2009, 9:2021-2028.
• [11]Roche S, Tiers L, Provansal M, Seveno M, Piva MT, Jouin P, Lehmann S: Depletion of one, six, twelve or twenty major blood proteins before proteomic analysis: the more the better? J Proteomics 2009, 72:945-951.
• [12]Ciron C, Desmaris N, Colle MA, Raoul S, Joussemet B, Verot L, Ausseil J, Froissart R, Roux F, Cherel Y, Lajat Y, Schwartz B, Vanier MT, Maire I, Tardieu M, Moullier P, Heard JM: Gene therapy of the brain in the dog model of Hurler’s syndrome. Ann Neurol 2006, 60:204-213.
• [13]Ellinwood NM, Ausseil J, Desmaris N, Bigou S, Liu S, Jens JK, Snella EM, Mohammed EEA, Thomson CB, Raoul S, Joussemet B, Roux F, Cherel Y, Lajat Y, Piraud M, Benchaouir R, Hermening S, Petry H, Froissart R, Tardieu M, Ciron C, Moullier P, Parkes J, Kline KL, Maire I, Vanier MT, Heard JM, Colle MA: Safe, efficient, and reproducible gene therapy of the brain in the dog models of sanfilippo and hurler syndromes. Mol Ther 2011, 19:251-259.
• [14]Barthelemy I, Uriarte A, Drougard C, Unterfinger Y, Thibaud JL, Blot S: Effects of an immunosuppressive treatment in the GRMD dog model of duchenne muscular dystrophy. PLoS One 2012, 7(11):e48478.
• [15]Nakamura K, Miyasho T, Nomura S, Yokota H, Nakade T: Proteome analysis of cerebrospinal fluid in healthy beagles and canine encephalitis. J Vet Med Sci 2012, 74:751-756.
• [16]Shafie INF, Anderson TJ, Penderis J, Eckersall PD, McLaughlin M: A protocol for the management of canine cerebrospinal fluid for the proteomic assessment of putative biomarkers. Vet J 2013, 197:836-841.
• [17]Chen RL, Sage EA, Dunn MJ, Wait R, Preston JE: Optimising ovine cerebrospinal fluid preparation for two-dimensional gel electrophoresis. Proteomics 2006, 6:3170-3175.
• [18]Lange S, Sylvester M, Schumann M, Freund C, Krause E: Identification of phosphorylation-dependent interaction partners of the adapter protein ADAP using quantitative mass spectrometry: SILAC vs O-18-labeling. J Proteome Res 2010, 9:4113-4122.
• [19]Pottiez G, Ciborowski P: Proteomic profiling of cerebrospinal fluid. In Expression profiling in neuroscience. Edited by Karamanos Y. New York, NY, USA: Humana Press; 2012:245-270. [Walz W (Series Editor): Neuromethods, vol 13.]
• [20]Shores KS, Knapp DR: Assessment approach for evaluating high abundance protein depletion methods for cerebrospinal fluid (CSF) proteomic analysis. J Proteome Res 2007, 6:3739-3751.
• [21]Holewinski RJ, Jin ZC, Powell MJ, Maust MD, Van Eyk JE: A fast and reproducible method for albumin isolation and depletion from serum and cerebrospinal fluid. Proteomics 2013, 13:743-750.
• [22]Fortin T, Salvador A, Charrier JP, Lenz C, Lacoux X, Morla A, Choquet-Kastylevsky G, Lemoine J: Clinical quantitation of prostate-specific antigen biomarker in the Low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests. Mol Cell Proteomics 2009, 8:1006-1015.
• [23]Bjorhall K, Miliotis T, Davidsson P: Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples. Proteomics 2005, 5:307-317.
• [24]Higuchi M, Iwata N, Matsuba Y, Takano J, Suemoto T, Maeda J, Ji B, Ono M, Staufenbiel M, Suhara T, Saido TC: Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology. FASEB J 2012, 26:1204-1217.
• [25]Schutzer SE, Liu T, Natelson BH, Angel TE, Schepmoes AA, Purvine SO, Hixson KK, Lipton MS, Camp DG, Coyle PK, Smith RD, Bergquist J: Establishing the proteome of normal human cerebrospinal fluid. PLoS One 2010, 5(6):e10980.